Navigation Links
Oral bisphosphonate did not improve prognosis for patients with breast cancer
Date:12/7/2011

SAN ANTONIO Results from a German study demonstrated no improvement in disease-free survival among patients with breast cancer who were treated with dose-dense chemotherapy and the bisphosphonate ibandronate.

Volker Mbus, Ph.D., head of the department of obstetrics and gynecology at Klinikum Frankfurt Hchst GmbH in Frankfurt, presented the results from the German Adjuvant Intergroup Node Positive (GAIN) Study, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

Mbus and his colleagues randomly assigned 3,023 patients with breast cancer to two different chemotherapy regimens and then further assigned them to 50 milligrams of oral ibandronate or observation. After a median follow-up of 38.7 months, "we found no significant difference between groups in the primary endpoint" of disease-free survival, Mbus said.

He described these results as "disappointing" compared with other studies. In the Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer (AZURE) trial, for example, Mbus said that the subgroup of postmenopausal patients showed an improvement in recurrence-free and overall survival.

"So far, clinical trials of adjuvant bisphosphonates in early breast cancer have shown variable results, independent from their application (oral compared with intravenous)," Mbus said.

More recently, two trials the Austrian Breast & Colorectal Study Group (ABCSG-12) and the Zometa-Femara Adjuvant Synergy Trial (ZO-FAST) have shown significant benefit in patients with hormone receptor-positive breast cancer who were postmenopausal and received an endocrine treatment only.

Mbus said that in the AZURE trial, 95 percent of patients received chemotherapy and only postmenopausal patients showed an improvement in the zoledronic acid group. "In our [GAIN] trial, all patients received dose-dense chemotherapy, and unfortunately, we could not show a benefit in any subgroup," he said. "We speculate that the high efficacy of dose-dense chemotherapy erases the potential effect of bisphosphonates, which is shown in patients with endocrine treatment only."


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Some bisphosphonates users unfamiliar with drugs possible side effects on oral health
2. New task force report on bisphosphonate use and atypical femur fractures in osteoporosis patients
3. Immediate bisphosphonate use with endocrine therapy reduced recurrence and increased survival in postmenopausal early breast cancer
4. A New Website Series Improves Appearance and Health City by City
5. CustomerCentric Selling and Kadient Announce Joint Event in Boston to Launch Strategic Partnership for Sales Enablement and Improvement
6. Exercise Success for People Over 50: Reports of Improved Fitness, Circulation and Balance
7. NationalCreditReport.com Reminds Consumers of Ways to Improve Credit Report and Score in 2010
8. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
9. Retired Military Brass Support First Ladys Call to Reduce Child Obesity, Improve Nutrition
10. NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education
11. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate ... the electrifying line-up of events for its annual meeting “Coming Home 2017,” an ... “Coming Home 2017” will be held on Friday January 27 through Sunday, ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... medical office in Petaluma, located at 167 Lynch Creek Way. The Petaluma office ... SRO sports medicine and rehabilitation services and on-site x-ray services. Two multi-specialist ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... by Austin, Texas Periodontist Dr. Dan Holtzclaw in media for its creos™ line ... two surgeries performed by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone ...
(Date:1/20/2017)... Hagerstown, MD (PRWEB) , ... January 20, 2017 , ... ... people to donate items they no longer use or need, from clothes to couches ... up any unwanted items and take them to the nearest Goodwill donation center through ...
(Date:1/20/2017)... ... 20, 2017 , ... Source Vitál Apothecary, a skin and body care company ... the company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports ... work in the nutritional, sports and health industries a chance to meet in private ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in ... medical device technologies. BCC Research reveals in its new report ... region, should see strong growth due to rising government healthcare spending, ... Continue Reading ... ...
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is expected to reach a ... is anticipated to drive the market growth in the coming years. Increasing adoption ... the recent years. Continue Reading ... ... ...
(Date:1/23/2017)... janvier 2017  ResMed (NYSE : RMD), BMC (Pékin, Chine) ... annoncé aujourd,hui qu,ils se sont mis d,accord sur le ... parties. BMC et 3B seront autorisés à vendre leurs ... ResMed, et ResMed effectuera le paiement de la décision ... litige de Floride entre les deux parties. Le règlement ...
Breaking Medicine Technology: